近期，百洋医药集团宣布与全球放射外科手术机器人企业ZAP Surgical签署战略合作协议，双方的合作涵盖了股权投资、ZAP核心产品Zap-X火星舟放射外科手术机器人的规模化生产及商业化运营等内容。这一合作标志着Zap-X在全球放射治疗领域的发展迈出了重要一步，有望为更多患者提供精准、高效的放射治疗服务。
### Zap-X：全球首创的放射治疗设备
Zap-X是全球首创的具有自屏蔽分析功能的放射治疗设备，于2018年通过我国创新医疗器械特别审批程序，受到广泛关注。其独特的设计将直线加速器与自屏蔽辐射结构结合于一体，无需传统辐射屏蔽设施的高昂成本，只需简单扩建即可提供即时放疗服务。这种创新设计从空间层面极大提高了放射治疗的普及可能，为全球范围内的放射治疗提供了新的解决方案。
### 提升靶向效率，保护正常组织
放射治疗的核心在于精准杀死肿瘤细胞的同时，保护正常组织不受损伤。Zap-X通过改良的准直器，实现了极少剂量进入非肿瘤目标区域，有效减少了副作用的可能性。其创新的机械设计可更好地保护肿瘤周围正常组织，缩短放疗时间，实现精确放射外科治疗。临床数据显示，Zap-X在临床上具有明显优势，治疗后效果显著，且无术后感染风险。
### 百洋医药集团的创新战略
百洋医药集团作为“产业投资人”，近年来积极与国内外头部创新力量合作，聚焦创新药、高端医疗器械、基础研究平台三大价值赛道，挖掘真正具备技术壁垒的源头创新并投资孵化，助力医疗行业改革创新。通过与ZAP Surgical的战略合作，百洋医药集团将充分发挥自身在医药健康领域的创新活力和产业敏锐度，推动Zap-X的规模化生产与商业化运营，为全球放射治疗领域带来新的发展动力。
### 结语
此次百洋医药集团与ZAP Surgical的战略合作，不仅体现了双方在放射治疗领域内的技术与市场优势互补，更是推动了全球放射治疗技术的创新与发展。通过共同推动Zap-X的规模化生产与商业化运营，双方有望为全球患者提供更加精准、高效、安全的放射治疗服务，进一步提升放射治疗的普及与应用水平，为全球医疗健康事业贡献重要力量。
英语如下：
### “Bi洋医药 Group Partners with ZAP Surgical to Scale Up Production and Commercialize Radiotherapy Robot Zap-X”
**Keywords**: Bi洋医药, Zap-X, Strategic Partnership
### **Bi洋医药 Group and ZAP Surgical Forge Strategic Alliance to Advance Large-Scale Production and Commercial Operations of Radiotherapy Robot Zap-X**
Recently, Bi洋医药 Group announced a strategic partnership with global robotic surgical company ZAP Surgical, covering equity investments, the large-scale production of ZAP’s flagship product, the Zap-X Mars Boat radiotherapy robot, and its commercial operations. This partnership signifies a significant step forward in the global field of radiotherapy, aiming to provide more patients with precise and efficient radiotherapy services.
### **Zap-X: A Global Innovation in Radiotherapy Equipment**
Zap-X is a pioneering radiotherapy device that integrates linear accelerators with self-shielding radiation structures, introduced to the market in 2018 through China’s innovative medical device approval process, attracting considerable attention. Its unique design combines the traditional radiation source with self-shielding structures, eliminating the need for costly radiation shielding facilities. This innovative design significantly enhances the potential for the widespread adoption of radiotherapy, offering a new solution to global radiotherapy challenges.
### **Enhancing Target Efficiency and Protecting Normal Tissues**
The core of radiotherapy lies in precisely killing cancer cells while sparing normal tissues. Zap-X improves on this by using a modified collimator that minimizes radiation dose to non-cancerous areas, significantly reducing the risk of side effects. Its innovative mechanical design better protects surrounding normal tissues, shortens treatment times, and achieves precise radio-surgical therapy. Clinical data shows that Zap-X offers clear advantages in clinical applications, with significant post-treatment effects and no risk of postoperative infection.
### **Bi洋医药 Group’s Innovation Strategy**
As an “industry investor,” Bi洋医药 Group has recently collaborated with leading innovation forces both domestically and internationally, focusing on innovation drugs, high-end medical devices, and foundational research platforms. It invests in and incubates true source innovations with strong technical barriers, driving innovation and reform in the medical industry. Through this strategic partnership with ZAP Surgical, Bi洋医药 Group will leverage its innovative vitality and industry acumen in the healthcare sector to accelerate the large-scale production and commercialization of Zap-X, contributing to the global development of radiotherapy technology.
### **Conclusion**
The strategic partnership between Bi洋医药 Group and ZAP Surgical not only highlights the complementary technical and market advantages of both parties in the field of radiotherapy but also drives innovation and development in global radiotherapy technology. By jointly advancing the large-scale production and commercialization of Zap-X, both parties are expected to provide global patients with more precise, efficient, and safe radiotherapy services, further enhancing the accessibility and application of radiotherapy worldwide, and contributing significantly to the global healthcare industry.
【来源】http://www.chinanews.com/life/2024/07-22/10255251.shtml
Views: 1